Administering scFv-mPAC in combinationwith LFN-Trp1-gp100 in B16–F10 murine melanoma demonstrateda significant abrogation of tumor growth and tumor depigmentation,which was accompanied by a significant extension of survival (26 dayscompared to 18 and 20 days for the controls). This evidence concerns the gene PMEL and melanoma.